Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma.
暂无分享,去创建一个
R. Greil | H. Eich | R. Müller | V. Diehl | H. Müller-Hermelink | B. Dörken | A. Ganser | C. Bokemeyer | J. Debus | M. Eble | L. Trümper | K. Willborn | P. Borchmann | B. Berger | A. Engert | H. Kirchner | A. Plütschow | A. Lohri | M. Wilhelm | M. Sökler | A. Ho | A. Rank | J. Schubert | Z. Král | M. Fuchs | H. Müller-hermelink
[1] P. Davis,et al. Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] S. A. Bush,et al. High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis. , 2003, Blood.
[3] F. d'Amore,et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] J. Yahalom. Don't throw out the baby with the bathwater: on optimizing cure and reducing toxicity in Hodgkin's lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] J. Raemaekers,et al. Chemotherapy plus involved-field radiation in early-stage Hodgkin's disease. , 2007, The New England journal of medicine.
[6] G. Canellos. Chemotherapy alone for early Hodgkin's lymphoma: an emerging option. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] C. Sebban,et al. Comparison of Three Radiation Dose Levels after EBVP Regimen in Favorable Supradiaphragmatic Clinical Stages (CS) I-II Hodgkin’s Lymphoma (HL): Preliminary Results of the EORTC-GELA H9-F Trial. , 2005 .
[8] H. Eich,et al. Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: final results of the GHSG HD7 trial. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] E. Noordijk,et al. Clinical stages I and II Hodgkin's disease: a specifically tailored therapy according to prognostic factors. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] J. Connors,et al. State-of-the-art therapeutics: Hodgkin's lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] P. Dupont,et al. Can positron emission tomography with [18F]‐fluorodeoxyglucose after first‐line treatment distinguish Hodgkin's disease patients who need additional therapy from others in whom additional therapy would mean avoidable toxicity? , 2001, British journal of haematology.
[12] A. Avilés,et al. A prospective clinical trial comparing chemotherapy, radiotherapy and combined therapy in the treatment of early stage Hodgkin's disease with bulky disease. , 1998, Clinical and laboratory haematology.
[13] John McGrath,et al. Hodgkin’s Disease , 1933, JAMA.
[14] J. Armitage,et al. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. , 1998, The New England journal of medicine.
[15] J. Friedberg,et al. Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] A. Zelenetz,et al. Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. , 2004, Blood.
[17] C. Bloomfield,et al. Chemotherapy and combined modality therapy for Hodgkin's disease: a progress report on Cancer and Leukemia Group B studies. , 1982, Cancer treatment reports.
[18] V. Diehl,et al. Second malignancy risk associated with treatment of Hodgkin's lymphoma: meta-analysis of the randomised trials. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[19] R Peto,et al. Influence of more extensive radiotherapy and adjuvant chemotherapy on long-term outcome of early-stage Hodgkin's disease: a meta-analysis of 23 randomized trials involving 3,888 patients. International Hodgkin's Disease Collaborative Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] J. Raemaekers,et al. Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] J. Connors,et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] H. Amthauer,et al. Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. , 2008, Blood.
[23] M. Maschio,et al. Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I-II Hodgkin's disease. , 1988, Journal of the National Cancer Institute.
[24] A. Hagenbeek,et al. Long-term risk of second malignancy in survivors of Hodgkin's disease treated during adolescence or young adulthood. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] G. Bonadonna,et al. Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP , 1975, Cancer.
[26] Martin Hutchings,et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. , 2006, Blood.
[27] S. Pileri,et al. Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[28] A. Zauber,et al. Incidence of second cancers in patients treated for Hodgkin's disease. , 1995, Journal of the National Cancer Institute.
[29] Dirk Hasenclever,et al. Involved-field radiotherapy is equally effective and less toxic compared with extended-field radiotherapy after four cycles of chemotherapy in patients with early-stage unfavorable Hodgkin's lymphoma: results of the HD8 trial of the German Hodgkin's Lymphoma Study Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.